Organigram FY2025 EPS Forecast Lowered by Atb Cap Markets

Key Points

• Atb Cap Markets has decreased its FY2025 earnings estimate for Organigram Holdings from $0.10 to $0.07 per share, while the consensus estimate is $0.16 per share.
• Organigram's stock has experienced a 6.1% decline in trading, opening at C$2.01, with a 52-week low of C$1.22 and a high of C$2.84.
• The company, a licensed producer of cannabis products in Canada, has a market capitalization of C$248.32 million and a debt-to-equity ratio of 3.07.

Organigram Holdings Inc. (TSE:OGI - Free Report) - Investment analysts at Atb Cap Markets decreased their FY2025 EPS estimates for Organigram in a research note issued to investors on Wednesday, August 13th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings per share of $0.07 for the year, down from their previous estimate of $0.10. The consensus estimate for Organigram's current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram's FY2027 earnings at $0.06 EPS.

Organigram Stock Up 1.4%

Shares of OGI stock traded up C$0.03 during trading hours on Monday, hitting C$2.20. 221,207 shares of the company's stock traded hands, compared to its average volume of 173,654. The stock's fifty day simple moving average is C$1.97 and its two-hundred day simple moving average is C$1.77. Organigram has a 12-month low of C$1.22 and a 12-month high of C$2.77. The stock has a market cap of C$271.79 million, a price-to-earnings ratio of -4.65, a PEG ratio of 0.42 and a beta of 1.13. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07.

About Organigram

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.